2010 Lymphoma Research Findings Presented at the ASH Annual Meeting
The 52nd Annual Meeting of the American Society of Hematology (ASH) was held December 4-7, 2010 at the Orange County Convention Center in Orlando, Florida. The conference was the venue for the presentation of much of the year’s breakthrough research on lymphoma and other blood-related disorders. The lymphoma community anxiously awaits the discoveries announced at ASH each year and the Lymphoma Research Foundation (LRF) has compiled summaries of the most important findings to provide a general understanding of the biggest advances in lymphoma research in 2010.
Phase II Trial of New Drug Brentuximab Vedotin (SGN-35) Presented With Promising Results for Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients
At perhaps the most anticipated and buzzed about lymphoma presentation at the 52nd American Society of Hematology (ASH) annual meeting, researchers from across the world introduced results from a Phase II study of brentuximab vedotin (SGN-35), a new drug with the potential to change the lives of patients with relapsed or refractory Hodgkin lymphoma (HL).
Oral Drug Trial for Relapsed/Refractory Hodgkin Lymphoma Finds Positive Results
A multicenter Phase II study on the oral drug Panobinostat (LBH589), found effective anti-tumor activity in post-transplant relapsed/refractory Hodgkin lymphoma (HL) patients.
Phase III Trial Compares ABVD and Stanford V Regimens’ Efficacy in Hodgkin Lymphoma
The combination of drugs known as ABVD should remain the standard of care for Hodgkin Lymphoma, since the regimen known as Stanford V did not meet their failure free survival (FFS) objectives
Rituximab Reduces Need for New Treatment in Asymptomatic Follicular Lymphoma
Patients with asymptomatic, non-bulky follicular lymphoma (FL) have less of a chance of needing chemotherapy when treated at the time of diagnosis with rituximab, in comparison to a watch and wait strategy.
New Standard of Care for MCL Patients Under 65 Years Recommended by European MCL Network Trial
In the results of its second randomized trial, the European MCL Network found that high-dose chemotherapy followed by an ASCT resulted in a significant increase in progression-free survival in patients less than 65 years of age with advanced stage MCL.
Back to Research News